Skip to main content
. 2020 May 18;105(7):e2346–e2357. doi: 10.1210/clinem/dgaa246

Figure 3.

Figure 3.

Overall survival as a function of: A, TP53 mutation patients vs all other patients lacking TP53 mutations, B, TERT promoter mutation patients vs all other patients lacking TERT promoter mutations, C, BRAFVB600E mutation patients vs all other patients lacking BRAFV600E mutations, or D, BRAFVB600E plus TERT promoter mutation patients vs all other patients lacking BRAFV600E plus TERT promoter mutations.